


### NCI's Challenge



\* BRDPI: Biomedical Research and Development Price Index (http://officeofbudget.od.nih.gov)



## NCI FY 2008 Operating Budget: NCI Operating Policies

#### **NCI** operating policies

- Most ongoing grants will receive a 1% cost-ofliving increase from the FY07 level.
- Some grants in certain formats (modular grants)
  will receive the full amount for FY08.
- NCI will award fewer new grants than in FY 2007 (1,312 to 1,283)



### NCI FY 2008 Operating Budget: NCI Paylines

### **NCI** Paylines

- Traditional Research Grant (R01): 12<sup>th</sup> percentile
- Traditional Research Grant for a New Investigator (\*R01s):
   19<sup>th</sup> percentile (will hit NIH target)
- Multi-part, large grants (Program Project grants or PO1s): Selected on a case-by-case basis



### NCI FY 2008 Operating Budget:

### **NCI Programs Held to FY07 Levels:**

- Cancer Centers
- SPOREs (Specialized Programs of Research Excellence)
- Cooperative Groups



#### Office of Centers, Training, and Resources

- Integrating Aging and Cancer Research (co-funded with NIA)
  - NCI funding of \$4M-\$5M will not be renewed
- Supplements for Imaging Response
  Assessment Teams in Cancer Centers
  - -NCI funding of \$2M will not be renewed



**Division of Cancer Control & Population Sciences** 

- Transdisciplinary Tobacco Use Research Centers
  - -FY2008 is final year of RFA, funded at \$7.2M. No proposed RFA renewal
  - -NCI is joining a NIDA PA; For TTURC program, anticipate spending \$2M-4M, rather than \$7.2M/yr
- Long Term Cancer Survivors research RFA
  - -FY2008 funding reduced by \$1.7M



#### **Division of Cancer Prevention**

- CCOP cancer treatment trial accrual
  - FY05: 7,948 patients
  - FY06: 6,402 patients
  - **FY07: 6,100 patients (estimate)**
- CCOP cancer prevention & control trials:
  - FY05: 5,211 patients
  - FY06: 4,994 patients
  - FY07: 4,500 patients (estimate)



#### **Division of Cancer Treatment and Diagnosis**

- CTEP Interdisciplinary Research Teams for Molecular Target Assessment
  - -Eliminated in FY07; \$1.4M
- Cancer Imaging Program's Development of Contract Imaging Drugs and Enhancers
  - -Eliminated in FY07; \$1.6M
- Cancer Diagnosis Program: breast and prostate cancer tissue resources unfunded or eliminated
  - Prostate eliminated FY07; breast unfunded extension (combined max. funding \$3.25M/yr)



#### **Division of Cancer Treatment and Diagnosis**

- Data Resource for Analyzing Blood and Marrow Transplants
  - Approved for funding at proposed level for FY08 (\$600K)
  - -~80% of proposed level for FY09 FY12 (savings of approximately \$470K each fiscal year)



### FY 2009 President's Budget

FY08 NCI appropriation	\$4,805,088
FY 2009 PB for NCI	\$4,809,088
Difference '08 to '09	\$4,000
Percent Change '08 to'09	+0.1%

(dollars in thousands)



### NCI's Opportunities

- Never a more exciting time in science
- Will completely change diagnosis of disease and therapy
- There will be great opportunities for prevention to extend life
- Therapy highly personalized and developed as treatment solutions

Rapidly advancing technology will transform the conduct of science.



### National Cancer Institute

- To preempt development of cancer at every opportunity
- To drive science toward the creation of new knowledge
- To ensure access to our latest science for all people
- To ensure the best outcome for each patient

